FDA grants Gilead two first-line approvals for Trodelvy in triple-negative breast cancer, broadening its reach beyond Datroway's narrower indication.
One month after Daiichi Sankyo and AstraZeneca’s drug Datroway received a key breast cancer approval from the FDA, the agency has granted Gilead two approvals …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an…
The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi…
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of…
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with…
